JP2010512320A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010512320A5 JP2010512320A5 JP2009540313A JP2009540313A JP2010512320A5 JP 2010512320 A5 JP2010512320 A5 JP 2010512320A5 JP 2009540313 A JP2009540313 A JP 2009540313A JP 2009540313 A JP2009540313 A JP 2009540313A JP 2010512320 A5 JP2010512320 A5 JP 2010512320A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- monoclonal antibody
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87383406P | 2006-12-08 | 2006-12-08 | |
| US60/873,834 | 2006-12-08 | ||
| PCT/US2007/025080 WO2008073300A2 (en) | 2006-12-08 | 2007-12-06 | Monoclonal antibodies against angptl3 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010512320A JP2010512320A (ja) | 2010-04-22 |
| JP2010512320A5 true JP2010512320A5 (enExample) | 2011-01-27 |
| JP5484063B2 JP5484063B2 (ja) | 2014-05-07 |
Family
ID=39512267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540313A Expired - Fee Related JP5484063B2 (ja) | 2006-12-08 | 2007-12-06 | Ａｎｇｐｔｌ３に対するモノクローナル抗体 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7935796B2 (enExample) |
| EP (1) | EP2121751B1 (enExample) |
| JP (1) | JP5484063B2 (enExample) |
| KR (1) | KR101503937B1 (enExample) |
| CN (1) | CN101855241B (enExample) |
| AR (1) | AR064205A1 (enExample) |
| AU (1) | AU2007332855B2 (enExample) |
| BR (1) | BRPI0720218A2 (enExample) |
| CA (1) | CA2672049C (enExample) |
| DK (1) | DK2121751T3 (enExample) |
| EA (1) | EA019661B1 (enExample) |
| ES (1) | ES2618830T3 (enExample) |
| HU (1) | HUE033960T2 (enExample) |
| IL (1) | IL199216A (enExample) |
| MX (1) | MX2009006082A (enExample) |
| NO (1) | NO20092215L (enExample) |
| PL (1) | PL2121751T3 (enExample) |
| PT (1) | PT2121751T (enExample) |
| TW (1) | TW200846364A (enExample) |
| WO (1) | WO2008073300A2 (enExample) |
| ZA (1) | ZA200904022B (enExample) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200904022B (en) * | 2006-12-08 | 2010-08-25 | Lexicon Pharmaceuticals Inc | Monoclonal antibodies against ANGPTL3 |
| US9388414B2 (en) | 2008-10-08 | 2016-07-12 | Trustees Of Dartmouth College | Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases |
| US9149492B2 (en) | 2008-10-08 | 2015-10-06 | Trustees Of Dartmouth College | Method for selectively inhibiting ACAT1 in the treatment of alzheimer's disease |
| WO2010042292A1 (en) * | 2008-10-08 | 2010-04-15 | Trustees Of Dartmouth College | Method for selectively inhibiting the activity of acat1 in the treatment of alzheimer's disease |
| US9388413B2 (en) | 2008-10-08 | 2016-07-12 | Trustees Of Dartmouth College | Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases |
| US8802646B2 (en) | 2008-10-08 | 2014-08-12 | Trustees Of Dartmouth College | Method for selectively inhibiting the activity of ACAT1 in the treatment of alzheimer's disease |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| CN101852805B (zh) * | 2009-03-31 | 2015-04-01 | 浙江大学 | Angptl3作为卵巢癌的诊断标记物的用途 |
| AU2015200969A1 (en) * | 2010-01-08 | 2015-03-19 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| WO2011085271A2 (en) * | 2010-01-08 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| CA2826563C (en) * | 2011-02-07 | 2020-10-20 | Paul Kussie | Methods and systems for treating eclampsia and pre-eclampsia |
| WO2012154983A2 (en) | 2011-05-10 | 2012-11-15 | Biocare Medical, Llc | Systems and methods for anti-pax8 antibodies |
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| CA2839573A1 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
| CA3141978A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| ES2773111T3 (es) | 2011-09-16 | 2020-07-09 | Regeneron Pharma | Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a) |
| US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
| SI3495387T1 (sl) | 2012-07-13 | 2021-12-31 | Roche Glycart Ag | Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil |
| NZ704771A (en) | 2012-08-13 | 2018-02-23 | Regeneron Pharma | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| ES2682345T3 (es) | 2012-09-27 | 2018-09-20 | Biocare Medical, Llc | Sistemas y procedimientos de anticuerpos antiuroplaquina II |
| GB201219487D0 (en) * | 2012-10-30 | 2012-12-12 | Cancer Rec Tech Ltd | Anti-S100A4 antibody molecules and their uses |
| WO2014100220A2 (en) | 2012-12-18 | 2014-06-26 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
| DK2962113T3 (da) | 2013-02-28 | 2019-07-01 | Biocare Medical Llc | Systemer og fremgangsmåder med anti-p40-antistoffer |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| US9301971B2 (en) | 2013-03-08 | 2016-04-05 | Novartis Ag | Peptides and compositions for treatment of joint damage |
| UY35368A (es) | 2013-03-08 | 2014-10-31 | Irm Llc | Péptidos y composiciones para el tratamiento de daño articular |
| PL2992098T3 (pl) | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| US9816997B2 (en) | 2013-10-03 | 2017-11-14 | Biocare Medical, Llc | Anti-SOX10 antibody systems and methods |
| ES2754209T3 (es) | 2013-12-13 | 2020-04-16 | Stora Enso Oyj | Cartón multicapa |
| PL3087183T3 (pl) * | 2013-12-24 | 2021-01-11 | Ionis Pharmaceuticals, Inc. | Modulacja ekspresji białka angiopoetynopodobnego 3 |
| WO2015168589A2 (en) | 2014-05-01 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
| WO2015184105A1 (en) | 2014-05-29 | 2015-12-03 | Trustees Of Dartmouth College | Method for selectively inhibiting acat1 in the treatment of neurodegenerative diseases |
| US9527922B2 (en) * | 2014-12-31 | 2016-12-27 | Development Center For Biotechnology | Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy |
| BR112017021053A2 (en) | 2015-04-13 | 2018-08-14 | Alnylam Pharmaceuticals, Inc. | angiopoietin type 3 (angpt13) irna compositions and methods of use thereof |
| AU2016349625B2 (en) | 2015-11-06 | 2022-07-07 | Ionis Pharmaceuticals, Inc. | Modulating apolipoprotein (a) expression |
| IL260931B2 (en) * | 2016-02-17 | 2024-09-01 | Regeneron Pharma | Methods of treating or preventing atherosclerosis by blocking ANGPTL3 |
| MA43734A (fr) | 2016-03-03 | 2018-11-28 | Regeneron Pharma | Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3 |
| CN109069633A (zh) | 2016-04-15 | 2018-12-21 | 宏观基因有限公司 | 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法 |
| MD3448426T2 (ro) * | 2016-04-28 | 2025-09-30 | Regeneron Pharma | Metode de tratament al pacienților cu hipercolesterolemie familială |
| AU2017350947B2 (en) * | 2016-10-28 | 2024-02-15 | Washington University | Anti-ApoE antibodies |
| CN107085112B (zh) * | 2017-05-10 | 2019-03-19 | 武汉圣润生物科技有限公司 | 一种用于检测白血病的试剂盒 |
| CN111699004A (zh) | 2018-02-06 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 眼科疾病的治疗 |
| WO2019195561A2 (en) * | 2018-04-06 | 2019-10-10 | BioLegend, Inc. | Anti-tetraspanin 33 agents and compositions and methods for making and using the same |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| TW202027794A (zh) | 2018-10-03 | 2020-08-01 | 瑞士商諾華公司 | 血管生成素樣３多肽之持續遞送 |
| CN119033684A (zh) | 2018-10-29 | 2024-11-29 | 豪夫迈·罗氏有限公司 | 抗体制剂 |
| TWI747098B (zh) | 2018-12-21 | 2021-11-21 | 美商美國禮來大藥廠 | 抗angptl3/8複合物抗體及其使用方法 |
| US12559551B2 (en) | 2019-05-24 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ANGPTL3 antibodies |
| CN112062845B (zh) * | 2019-06-10 | 2022-09-02 | 山东博安生物技术股份有限公司 | Angptl3结合片段及其用途 |
| US20220380425A1 (en) * | 2019-07-04 | 2022-12-01 | Cadila Healthcare Limited | Angptl3 based vaccine for the treatment of liver disease |
| WO2021041300A2 (en) * | 2019-08-23 | 2021-03-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| CN110938144B (zh) * | 2019-11-27 | 2022-07-26 | 复旦大学附属儿科医院 | 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途 |
| WO2021147984A1 (zh) | 2020-01-22 | 2021-07-29 | 江苏恒瑞医药股份有限公司 | 抗angptl3抗体及其应用 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2022109443A1 (en) * | 2020-11-23 | 2022-05-27 | The Regents Of The University Of Michigan | Single-chain antibody against flavivirus ns1 protein |
| BR112023017737A2 (pt) | 2021-03-04 | 2023-10-03 | Alnylam Pharmaceuticals Inc | Composições de irna de angiopoietina-semelhantes 3 (angptl3) e métodos de uso das mesmas |
| WO2022187353A1 (en) * | 2021-03-05 | 2022-09-09 | Anji Pharmaceuticals Inc. | Methods and compositions for treating sepsis |
| JPWO2022244845A1 (enExample) * | 2021-05-19 | 2022-11-24 | ||
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| US20240318176A1 (en) * | 2021-07-09 | 2024-09-26 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP2024525613A (ja) * | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
| AU2022314036A1 (en) * | 2021-07-21 | 2024-02-01 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition of anti-angptl3 antibody or antigen binding fragment thereof and its application |
| CN116284377A (zh) * | 2021-12-21 | 2023-06-23 | 复旦大学 | 抗人血管生成素3纳米抗体及其应用 |
| AU2023264772A1 (en) | 2022-05-02 | 2024-10-24 | Novo Nordisk A/S | Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration |
| CN117447592B (zh) * | 2022-07-26 | 2024-05-28 | 北京东方百泰生物科技股份有限公司 | 一种抗Siglec-15单克隆抗体、其抗原结合片段及其应用 |
| CN116199779B (zh) * | 2022-12-08 | 2023-08-11 | 北京东方百泰生物科技股份有限公司 | 一种抗lilrb4单克隆抗体、其抗原结合片段及其应用 |
| WO2024130165A1 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome |
| CN119192369A (zh) * | 2023-06-25 | 2024-12-27 | 百奥泰生物制药股份有限公司 | 抗angptl3抗体及其应用 |
| CN121971408B (zh) * | 2026-04-09 | 2026-07-28 | 浙江大学 | 一种膜仿生修饰的siRNA递送体系及其制备方法和应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| AU1674292A (en) | 1991-03-15 | 1992-10-21 | Synergen, Inc. | Pegylation of polypeptides |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5912000A (en) | 1994-09-23 | 1999-06-15 | Zonagen, Inc. | Chitosan induced immunopotentiation |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| TW313568B (enExample) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
| US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| US20030100051A1 (en) | 1998-05-12 | 2003-05-29 | Ruben Steven M. | 97 human secreted proteins |
| US5980912A (en) | 1997-03-25 | 1999-11-09 | Zonagen, Inc. | Chitosan induced immunopotentiation |
| US6030831A (en) * | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| AU4643699A (en) | 1998-06-24 | 2000-01-10 | Compugen Ltd. | Angiopoietin-like growth factor sequences |
| HUP0203408A3 (en) | 1999-12-09 | 2005-01-28 | Sankyo Co | Method of testing remedy or preventive for hyperlipemia |
| EP1403367A4 (en) | 2001-06-08 | 2005-08-17 | Sankyo Co | A MEDICAMENT TEST METHOD FOR TREATING OR PREVENTING DISEASES SUCH AS HYPERLIPEMIA |
| KR20100029861A (ko) | 2001-11-16 | 2010-03-17 | 제넨테크, 인크. | 안지오포이에틴-유사 단백질 3 ａｎｇｐｔｌ3을 함유하는 조성물 및 이를 사용하는 방법 |
| BRPI0606432A2 (pt) | 2005-01-07 | 2009-06-30 | Lexicon Pharmaceuticals Inc | anticorpos monoclonais contra angptl4 |
| ZA200904022B (en) * | 2006-12-08 | 2010-08-25 | Lexicon Pharmaceuticals Inc | Monoclonal antibodies against ANGPTL3 |
-
2007
- 2007-12-06 ZA ZA200904022A patent/ZA200904022B/xx unknown
- 2007-12-06 KR KR1020097013595A patent/KR101503937B1/ko not_active Expired - Fee Related
- 2007-12-06 EP EP07862629.8A patent/EP2121751B1/en active Active
- 2007-12-06 CA CA2672049A patent/CA2672049C/en active Active
- 2007-12-06 JP JP2009540313A patent/JP5484063B2/ja not_active Expired - Fee Related
- 2007-12-06 CN CN2007800511058A patent/CN101855241B/zh not_active Expired - Fee Related
- 2007-12-06 PT PT78626298T patent/PT2121751T/pt unknown
- 2007-12-06 PL PL07862629T patent/PL2121751T3/pl unknown
- 2007-12-06 EA EA200970556A patent/EA019661B1/ru not_active IP Right Cessation
- 2007-12-06 ES ES07862629.8T patent/ES2618830T3/es active Active
- 2007-12-06 AU AU2007332855A patent/AU2007332855B2/en not_active Ceased
- 2007-12-06 HU HUE07862629A patent/HUE033960T2/en unknown
- 2007-12-06 DK DK07862629.8T patent/DK2121751T3/en active
- 2007-12-06 BR BRPI0720218-0A2A patent/BRPI0720218A2/pt not_active Application Discontinuation
- 2007-12-06 US US12/001,012 patent/US7935796B2/en active Active
- 2007-12-06 MX MX2009006082A patent/MX2009006082A/es active IP Right Grant
- 2007-12-06 WO PCT/US2007/025080 patent/WO2008073300A2/en not_active Ceased
- 2007-12-07 AR ARP070105505A patent/AR064205A1/es active IP Right Grant
- 2007-12-07 TW TW096146844A patent/TW200846364A/zh unknown
-
2009
- 2009-06-07 IL IL199216A patent/IL199216A/en active IP Right Grant
- 2009-06-09 NO NO20092215A patent/NO20092215L/no not_active Application Discontinuation
-
2011
- 2011-03-28 US US13/073,617 patent/US8742075B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022031635A5 (enExample) | ||
| RU2504551C2 (ru) | Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста | |
| JP6964090B2 (ja) | Ａｎｇｐｔｌ８阻害剤およびａｎｇｐｔｌ３阻害剤を用いて高脂血症を処置するための方法 | |
| JP2010526028A5 (enExample) | ||
| JP2020169173A5 (enExample) | ||
| JP6321545B2 (ja) | 治療法における使用のための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| JP6321544B2 (ja) | 慢性若しくは急性疾患又は急性病態に罹患している患者の死亡リスクを低減するための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| JP6193871B2 (ja) | 慢性若しくは急性疾患又は急性病態に罹患している患者の臓器機能障害又は臓器不全を予防又は軽減するための、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| JP6224608B2 (ja) | 血液循環を安定化させるための、患者の急性疾患又は急性病態の治療法における使用に向けた、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| JP2009532336A5 (enExample) | ||
| JP2009511480A5 (enExample) | ||
| JP2026050358A (ja) | 治療用抗ｃｄ４０リガンド抗体 | |
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| JP2017507652A5 (enExample) | ||
| FI3569620T3 (fi) | Ihmisen cgrp-reseptoria sitovat vasta-aineet | |
| JP2011509245A5 (enExample) | ||
| JP2010043089A5 (enExample) | ||
| JP2011207882A5 (enExample) | ||
| RU2017145653A (ru) | Средства, пути применения и способы лечения синуклеопатии | |
| JP2018527903A5 (enExample) | ||
| CA2583910A1 (en) | Angiopoietin-2 specific binding agents | |
| JP2016509585A5 (enExample) | ||
| WO2015191934A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases | |
| JP2018529635A5 (enExample) | ||
| JP2017507131A5 (enExample) |